Enliven Therapeutics, Inc.
ELVN Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$43.69
KIRA · Stoqly’s AI analyst, in plain words
- Enliven Therapeutics, Inc. lost $104M in fiscal 2025.
- Free cash flow was −$70.5M in fiscal 2025, — of revenue.
Market cap
$2.9B
P/E
—
Revenue
—
Net income
−$104M
Free cash flow
−$70.5M
Operating margin
—
Enliven Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$104M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Enliven Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Enliven Therapeutics, Inc.
- CIK
- 0001672619
Enliven Therapeutics, Inc. · ELVN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$51.4M | −$37.7M | −$71.6M | −$89.0M | −$104M |
| Diluted EPS | −$2.37 | −$12.05 | −$2.01 | −$1.89 | −$1.83 |
| Cash | |||||
| Cash from operations | −$46.8M | −$32.1M | −$61.3M | −$73.2M | −$70.3M |
| Capital expenditure | $0.0M | $0.6M | $0.1M | $0.0M | $0.2M |
| Free cash flow | −$46.8M | −$32.7M | −$61.4M | −$73.2M | −$70.5M |
| Share count change | 55.6% | −85.6% | 1,037.7% | 32.4% | 20.4% |
| Debt and strength | |||||
| Cash and short-term investments | $90.3M | $75.5M | $253M | $313M | $463M |
| Shareholders' equity | −$42.9M | −$76.8M | $246M | $310M | $460M |
| Current ratio | 12.9x | 8.0x | 10.3x | 20.0x | 28.7x |
| Returns and quality | |||||
| Return on equity | −247.3% | — | −84.7% | −32.0% | −27.0% |
| Return on tangible equity | — | — | −29.1% | −28.7% | −22.6% |
| Altman Z'' | −8.8 | −8.8 | 11.8 | 21.9 | 31.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$76.9M
10 insiders
Of sales under plans
32%
$24.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Enliven Therapeutics, Inc. · ELVN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $43.69 a share, the company is worth $2.9B.
Source: SEC EDGAR XBRL filings (CIK 0001672619). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.